Skin toxicity as a risk factor for major infections in breast cancer patients treated with docetaxel
(2004) In Acta Oncologica 43(2). p.190-195- Abstract
- Docetaxel-related skin toxicity, oral and gastrointestinal mucosal toxicity, and changes in blood cell counts were investigated as predictive factors for major infections in 143 women treated with 3-weekly docetaxel (100 mg/m(2)) as second-line therapy for metastatic breast cancer in a randomized trial. Each patient with a major infection (n = 37) was compared with two controls. Skin toxicity (odds ratio 2.97, 95% CI 1.37 - 6.47), oral mucositis (1.98, CI 1.30 - 3.04), and the leukocyte nadir (0.12, CI 0.02 - 0.51) were significantly associated with a major infection in a univariate logistic regression analysis. In a multivariate analysis, skin toxicity was the only independent factor predictive for grade 3 to 4 infection ( 2.75, CI 1.00 -... (More)
- Docetaxel-related skin toxicity, oral and gastrointestinal mucosal toxicity, and changes in blood cell counts were investigated as predictive factors for major infections in 143 women treated with 3-weekly docetaxel (100 mg/m(2)) as second-line therapy for metastatic breast cancer in a randomized trial. Each patient with a major infection (n = 37) was compared with two controls. Skin toxicity (odds ratio 2.97, 95% CI 1.37 - 6.47), oral mucositis (1.98, CI 1.30 - 3.04), and the leukocyte nadir (0.12, CI 0.02 - 0.51) were significantly associated with a major infection in a univariate logistic regression analysis. In a multivariate analysis, skin toxicity was the only independent factor predictive for grade 3 to 4 infection ( 2.75, CI 1.00 - 7.58). A major infection was diagnosed in 62% ( 8 out of 13) of the docetaxel cycles in severely ( grade 4) leukopenic patients who had grade 2 to 4 skin toxicity. Major infections are common in leukopenic patients who develop docetaxel-associated skin toxicity, and leukopenic patients presenting with docetaxel-induced skin toxicity may be candidates for prophylactic anti-infection measures such as prophylactic therapy with hematopoietic growth factors. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/899186
- author
- Poikonen, P ; Sjostrom, J ; Klaar, S ; Nittby, LT ; Sigurdsson, H ; Madsen, EL ; Joensuu, H and Blomqvist, C
- publishing date
- 2004
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Acta Oncologica
- volume
- 43
- issue
- 2
- pages
- 190 - 195
- publisher
- Taylor & Francis
- external identifiers
-
- wos:000220516200010
- pmid:15163169
- scopus:11144353697
- ISSN
- 1651-226X
- DOI
- 10.1080/02841860310022977
- language
- English
- LU publication?
- no
- additional info
- The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Oncology, Malmö (ceased) (LUR000015)
- id
- ce518d05-4a10-464e-a9ed-ea3a09bf0020 (old id 899186)
- date added to LUP
- 2016-04-01 16:29:56
- date last changed
- 2022-01-28 20:06:53
@article{ce518d05-4a10-464e-a9ed-ea3a09bf0020,
abstract = {{Docetaxel-related skin toxicity, oral and gastrointestinal mucosal toxicity, and changes in blood cell counts were investigated as predictive factors for major infections in 143 women treated with 3-weekly docetaxel (100 mg/m(2)) as second-line therapy for metastatic breast cancer in a randomized trial. Each patient with a major infection (n = 37) was compared with two controls. Skin toxicity (odds ratio 2.97, 95% CI 1.37 - 6.47), oral mucositis (1.98, CI 1.30 - 3.04), and the leukocyte nadir (0.12, CI 0.02 - 0.51) were significantly associated with a major infection in a univariate logistic regression analysis. In a multivariate analysis, skin toxicity was the only independent factor predictive for grade 3 to 4 infection ( 2.75, CI 1.00 - 7.58). A major infection was diagnosed in 62% ( 8 out of 13) of the docetaxel cycles in severely ( grade 4) leukopenic patients who had grade 2 to 4 skin toxicity. Major infections are common in leukopenic patients who develop docetaxel-associated skin toxicity, and leukopenic patients presenting with docetaxel-induced skin toxicity may be candidates for prophylactic anti-infection measures such as prophylactic therapy with hematopoietic growth factors.}},
author = {{Poikonen, P and Sjostrom, J and Klaar, S and Nittby, LT and Sigurdsson, H and Madsen, EL and Joensuu, H and Blomqvist, C}},
issn = {{1651-226X}},
language = {{eng}},
number = {{2}},
pages = {{190--195}},
publisher = {{Taylor & Francis}},
series = {{Acta Oncologica}},
title = {{Skin toxicity as a risk factor for major infections in breast cancer patients treated with docetaxel}},
url = {{http://dx.doi.org/10.1080/02841860310022977}},
doi = {{10.1080/02841860310022977}},
volume = {{43}},
year = {{2004}},
}